vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and BRAND HOUSE COLLECTIVE, INC. (TBHC). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $103.5M, roughly 1.6× BRAND HOUSE COLLECTIVE, INC.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -9.6%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -21.0%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Soho House is an international private members’ club with a focus on the media, arts and fashion industries.
ESPR vs TBHC — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $103.5M |
| Net Profit | — | $-3.7M |
| Gross Margin | — | 20.4% |
| Operating Margin | 50.6% | -1.9% |
| Net Margin | — | -3.6% |
| Revenue YoY | 143.7% | -9.6% |
| Net Profit YoY | — | 51.8% |
| EPS (diluted) | $0.32 | $-0.16 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $103.5M | ||
| Q3 25 | $87.3M | $75.8M | ||
| Q2 25 | $82.4M | $81.5M | ||
| Q1 25 | $65.0M | $148.9M | ||
| Q4 24 | $69.1M | $114.4M | ||
| Q3 24 | $51.6M | $86.3M | ||
| Q2 24 | $73.8M | $91.8M | ||
| Q1 24 | $137.7M | $165.9M |
| Q4 25 | — | $-3.7M | ||
| Q3 25 | $-31.3M | $-20.2M | ||
| Q2 25 | $-12.7M | $-11.8M | ||
| Q1 25 | $-40.5M | $7.9M | ||
| Q4 24 | — | $-7.7M | ||
| Q3 24 | $-29.5M | $-14.5M | ||
| Q2 24 | $-61.9M | $-8.8M | ||
| Q1 24 | $61.0M | $10.1M |
| Q4 25 | — | 20.4% | ||
| Q3 25 | — | 16.3% | ||
| Q2 25 | — | 24.9% | ||
| Q1 25 | — | 30.3% | ||
| Q4 24 | — | 28.1% | ||
| Q3 24 | — | 20.5% | ||
| Q2 24 | — | 29.5% | ||
| Q1 24 | — | 32.0% |
| Q4 25 | 50.6% | -1.9% | ||
| Q3 25 | -11.4% | -24.7% | ||
| Q2 25 | 8.6% | -12.9% | ||
| Q1 25 | -34.0% | 6.2% | ||
| Q4 24 | -6.4% | -2.1% | ||
| Q3 24 | -31.0% | -15.4% | ||
| Q2 24 | 3.5% | -8.2% | ||
| Q1 24 | 52.5% | 6.4% |
| Q4 25 | — | -3.6% | ||
| Q3 25 | -35.9% | -26.6% | ||
| Q2 25 | -15.4% | -14.5% | ||
| Q1 25 | -62.2% | 5.3% | ||
| Q4 24 | — | -6.7% | ||
| Q3 24 | -57.2% | -16.8% | ||
| Q2 24 | -83.9% | -9.6% | ||
| Q1 24 | 44.3% | 6.1% |
| Q4 25 | $0.32 | $-0.16 | ||
| Q3 25 | $-0.16 | $-0.90 | ||
| Q2 25 | $-0.06 | $-0.54 | ||
| Q1 25 | $-0.21 | $0.61 | ||
| Q4 24 | $-0.14 | $-0.59 | ||
| Q3 24 | $-0.15 | $-1.11 | ||
| Q2 24 | $-0.33 | $-0.68 | ||
| Q1 24 | $0.34 | $0.80 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $6.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $-44.0M |
| Total Assets | $465.9M | $229.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $6.5M | ||
| Q3 25 | $92.4M | $3.6M | ||
| Q2 25 | $86.1M | $3.5M | ||
| Q1 25 | $114.6M | $3.8M | ||
| Q4 24 | $144.8M | $6.8M | ||
| Q3 24 | $144.7M | $4.5M | ||
| Q2 24 | $189.3M | $3.8M | ||
| Q1 24 | $226.6M | $3.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $64.0M | ||
| Q4 24 | — | $85.8M | ||
| Q3 24 | — | $61.4M | ||
| Q2 24 | — | $47.5M | ||
| Q1 24 | — | $34.0M |
| Q4 25 | $-302.0M | $-44.0M | ||
| Q3 25 | $-451.4M | $-35.2M | ||
| Q2 25 | $-433.5M | $-16.2M | ||
| Q1 25 | $-426.2M | $-19.0M | ||
| Q4 24 | $-388.7M | $-27.1M | ||
| Q3 24 | $-370.2M | $-19.7M | ||
| Q2 24 | $-344.2M | $-5.5M | ||
| Q1 24 | $-294.3M | $3.1M |
| Q4 25 | $465.9M | $229.2M | ||
| Q3 25 | $364.0M | $221.9M | ||
| Q2 25 | $347.1M | $225.4M | ||
| Q1 25 | $324.0M | $242.2M | ||
| Q4 24 | $343.8M | $279.8M | ||
| Q3 24 | $314.1M | $266.2M | ||
| Q2 24 | $352.3M | $242.6M | ||
| Q1 24 | $373.1M | $250.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 10.88× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $-25.9M |
| Free Cash FlowOCF − Capex | — | $-26.8M |
| FCF MarginFCF / Revenue | — | -25.9% |
| Capex IntensityCapex / Revenue | 0.0% | 0.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-18.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $-25.9M | ||
| Q3 25 | $-4.3M | $-7.0M | ||
| Q2 25 | $-31.4M | $-3.1M | ||
| Q1 25 | $-22.6M | $19.8M | ||
| Q4 24 | $-35.0M | $-12.6M | ||
| Q3 24 | $-35.3M | $-12.7M | ||
| Q2 24 | $-7.2M | $-13.7M | ||
| Q1 24 | $53.8M | $28.2M |
| Q4 25 | — | $-26.8M | ||
| Q3 25 | — | $-7.4M | ||
| Q2 25 | — | $-3.6M | ||
| Q1 25 | — | $19.0M | ||
| Q4 24 | — | $-13.1M | ||
| Q3 24 | $-35.5M | $-13.2M | ||
| Q2 24 | $-7.3M | $-14.4M | ||
| Q1 24 | $53.8M | $26.7M |
| Q4 25 | — | -25.9% | ||
| Q3 25 | — | -9.8% | ||
| Q2 25 | — | -4.5% | ||
| Q1 25 | — | 12.8% | ||
| Q4 24 | — | -11.5% | ||
| Q3 24 | -68.7% | -15.2% | ||
| Q2 24 | -9.9% | -15.7% | ||
| Q1 24 | 39.0% | 16.1% |
| Q4 25 | 0.0% | 0.9% | ||
| Q3 25 | 0.0% | 0.6% | ||
| Q2 25 | 0.0% | 0.7% | ||
| Q1 25 | 0.0% | 0.5% | ||
| Q4 24 | 0.0% | 0.4% | ||
| Q3 24 | 0.3% | 0.5% | ||
| Q2 24 | 0.1% | 0.8% | ||
| Q1 24 | 0.1% | 0.9% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 2.51× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | 2.79× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
TBHC
Segment breakdown not available.
